By Suherman Candra Maholtra 
The landscape of global vaccinology underwent a paradigm shift on December 8, 2020, when the first clinically approved messenger RNA (mRNA) vaccine for COVID-19 was administered. This milestone, achieved with unprecedented speed, served as a proof of concept for a technology that would eventually save an estimated 14.4 million lives within its first year of global distribution. However, as the world moves beyond the acute phase of the pandemic, the scientific community is confronting the inherent limitations of the mRNA-lipid nanoparticle (LNP) delivery system. In a significant leap forward for biotechnology, a multidisciplinary research team led by the Wyss Institute at Harvard University and the Dana-Farber Cancer Institute (DFCI) has unveiled a new vaccine platform known as DoriVac. Utilizing the principles of DNA origami, this platform offers a programmable, stable, and highly effective alternative that could redefine how humanity prepares for future viral threats.
The mRNA Legacy and the Necessity for Innovation
To understand the significance of the DoriVac platform, one must first examine the context provided by the COVID-19 pandemic. The rapid deployment of mRNA vaccines by Pfizer-BioNTech and Moderna was a triumph of modern science, yet the real-world application of these vaccines revealed several logistical and biological hurdles. While highly effective at preventing severe disease and death, mRNA-generated immunity has proven to be relatively short-lived, necessitating frequent booster shots. Furthermore, the SARS-CoV-2 virus has demonstrated a remarkable capacity for rapid mutation, leading to the emergence of variants that partially evade the immune defenses triggered by original vaccine formulations.
Beyond biological durability, the physical requirements of mRNA vaccines present a significant barrier to global health equity. The lipid nanoparticles used to encapsulate and protect the fragile mRNA molecules are chemically unstable, requiring a strict "cold chain" for transport and storage. Many mRNA formulations must be kept at temperatures as low as -80°C (-112°F), a requirement that is nearly impossible to meet in under-resourced regions or rural areas of the developing world. Additionally, the manufacturing process—specifically the precision required to package mRNA into LNPs—is notoriously complex and expensive, often leading to batch-to-batch variability and unintended off-target effects.
Introducing DoriVac: The DNA Origami Solution
In response to these challenges, researchers at the Wyss Institute, Dana-Farber, and their partner institutions turned to DNA nanotechnology. The DoriVac platform (short for DNA Origami Vaccine) represents a radical departure from traditional vaccine delivery. Instead of using lipid "bubbles" to carry genetic instructions, DoriVac utilizes a "DNA origami" chassis. This involves folding long strands of DNA into specific, rigid, three-dimensional shapes at the nanoscale.
These self-assembling square nanostructures act as a highly organized scaffolding. On one side of the structure, scientists can arrange adjuvant molecules—substances that "prime" the immune system—at precise nanometer distances. On the opposite side, they can attach specific antigens, such as peptides or proteins derived from a pathogen. This level of spatial control is unprecedented in vaccine design. By programming the exact distance between molecules, the researchers can optimize the way immune cells, such as dendritic cells, recognize and respond to the vaccine.
Targeting the Conserved HR2 Peptide
One of the most innovative aspects of the DoriVac study, recently published in Nature Biomedical Engineering, is its focus on the HR2 (heptad repeat 2) peptide region. While most current COVID-19 vaccines target the rapidly mutating receptor-binding domain (RBD) of the spike protein, the HR2 region is highly "conserved." This means it remains largely unchanged across various strains of SARS-CoV-2, as well as other dangerous viruses like HIV and Ebola.
By targeting a conserved region, the DoriVac platform aims to provide "broad-spectrum" protection. In preclinical trials involving mice, the SARS-CoV-2 HR2 DoriVac vaccine triggered a robust dual-layered immune response. This included "humoral" immunity, characterized by the production of high-titer antibodies, and "cellular" immunity, driven by T cells that can identify and destroy infected cells. The researchers noted that the numbers of antibody-producing B cells and activated antigen-presenting dendritic cells (DCs) were significantly higher in subjects treated with the DNA origami structure compared to those given the same antigens and adjuvants without the nanostructure.
Bridging the Gap: Human Organ-on-a-Chip Technology
A recurring problem in pharmaceutical development is the "translational gap"—the phenomenon where treatments that work perfectly in mice fail to produce the same results in humans. To mitigate this risk, the research team utilized the Wyss Institute’s proprietary microfluidic human Organ Chip technology. Specifically, they employed a "human lymph node-on-a-chip" (human LN Chip).
This system simulates the environment of a human lymph node in vitro, allowing researchers to observe how human immune cells interact with the vaccine in real-time. The results were compelling: the DoriVac vaccine activated human dendritic cells and induced a significant increase in inflammatory cytokines. Furthermore, it stimulated the proliferation of CD4+ and CD8+ T cells, which are essential for long-term immunological memory. This successful simulation suggests that the DoriVac platform is highly likely to translate effectively into human clinical trials.
Head-to-Head: DoriVac vs. mRNA Vaccines
In a pivotal phase of the study, the team conducted a direct comparison between the DoriVac platform and the established mRNA-LNP vaccines produced by Moderna and Pfizer/BioNTech. Using a standard booster protocol in mice, both vaccine types were tasked with delivering the full SARS-CoV-2 spike protein.
The data revealed that DoriVac produced immune activation comparable to that of the mRNA vaccines in terms of T cell and B cell responses. However, the DNA origami platform demonstrated clear superiority in logistical parameters. Unlike mRNA vaccines, DoriVac is inherently more stable and does not require extreme cold storage. It is also significantly easier to manufacture with high precision, as the self-assembling nature of DNA allows for consistent production of identical nanostructures.
"With the DoriVac platform, we have developed an extremely flexible chassis with a number of critical advantages," stated William Shih, Ph.D., a Wyss Institute Core Faculty member and Professor at Harvard Medical School. "Our study demonstrates DoriVac’s versatility and potential by taking a close look at the immune changes that are required to fight infectious viruses."
Chronology of Development and Collaborative Efforts
The development of DoriVac is the result of years of interdisciplinary collaboration. The technology was initially conceptualized for oncology applications. In early 2024, Shih’s team and Dr. Yang (Claire) Zeng introduced DoriVac as a cancer vaccine platform, showing that it could precisely present tumor-specific antigens to the immune system.
When the COVID-19 pandemic struck, the team pivoted to explore whether the platform’s superior adjuvant activity could be applied to infectious diseases. Dr. Zeng, who is now the co-founder and CEO/CTO of DoriNano, led this transition. She collaborated with Dr. Donald Ingber, whose lab at the Wyss Institute specializes in AI-driven antiviral innovation and Organ Chip technology. By combining DNA nanotechnology with advanced human cellular models, the team was able to accelerate the development of vaccines for SARS-CoV-2, HIV, and Ebola simultaneously.
Global Health Implications and Future Outlook
The implications of a successful DNA origami vaccine platform are vast. From a public health perspective, the ability to store vaccines at room temperature or in standard refrigeration could solve the "last mile" delivery problem that has hampered vaccination efforts in the Global South. Furthermore, the programmable nature of DoriVac means that if a new "Virus X" emerges, scientists could theoretically swap out the antigen on the DNA chassis and have a stable, mass-producible vaccine ready in weeks.
The safety profile of DoriVac also appears promising. Because the platform uses DNA—a biological material the body is already equipped to handle—the risk of the inflammatory side effects sometimes associated with synthetic lipid nanoparticles may be reduced. Recent studies at DoriNano have focused on confirming this safety profile as the technology moves toward the clinical stage.
Dr. Donald Ingber emphasized the importance of this technological convergence: "The predictive capabilities of human LN Chips gave us an ideal testing ground… This convergence of technologies enabled us to dramatically raise the chances of success for a new class of vaccines and create a new testbed for future vaccine developments."
As the world prepares for the next inevitable pandemic, the focus is shifting from reactive measures to proactive, versatile platforms. The DoriVac platform, with its combination of structural precision, biological efficacy, and logistical resilience, stands as a frontrunner in the next generation of medical countermeasures. The research, supported by various institutions including the National Institutes of Health and the Bill and Melinda Gates Foundation, signals a future where vaccines are not only life-saving but also globally accessible and adaptable to the ever-evolving microbial world.
